Hackensack

385 Prospect Avenue Suite 101 Hackensack, NJ, 07601

ORDERING PROVIDER Signature X

Princeton / Somerset 49 Veronica Avenue Suite 202 Somerset, NJ 08873

Long Branch 422 Morris Avenue Suite 7 Long branch, NJ 07740

Marlton 127 Church Road Suite 600 Marlton, NJ 08053



NPI\_



TREMFYA (guselkumab) ORDER FORM Date: \_\_\_\_\_ PATIENT INFORMATION DOB: SEX: M □ F □ Phone: Name: □NKDA Allergies: Weight lbs/kg: PHYSICIAN INFORMATION Physician Name\*: Practice Name: Address: Office Contact Name: Office Contact #: Phone: Email (for updates): Fax: **REFERRAL STATUS** ☐Referral Renewal ☐ Benefits Verification Only □New Referral ☐ Medication/Order Change □ Discontinuation Order TREMFYA: is an interleukin-23 antagonist indicated for the treatment of adult patients with: Moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy • Active psoriatic arthritis • Moderately to severely active ulcerative colitis **DOSAGE AND ADMINISTRATION: DOSAGE FORMS AND STRENGTHS:** Use the lowest effective recommended dosage to **Recommended Evaluations and Immunizations Prior to Treatment** maintain therapeutic response Initiation Subcutaneous Injection • MEvaluate patients for tuberculosis (TB) infection prior to initiating • Injection: 100 mg/mL in a single-dose One-Press treatment with TREMFYA patient-controlled injector. • Complete all age-appropriate vaccinations according to current Injection: 200 mg/2 mL in a single-dose prefilled pen immunization guidelines [see Warnings and Precautions. (TREMFYA PEN). Recommended Dosage • Injection: 100 mg/mL in a single-dose prefilled syringe. Plaque Psoriasis • Injection: 200 mg/2 mL in a single-dose prefilled syringe. • 100 mg administered by subcutaneous injection at Week 0. Week 4. Intravenous Infusion and every 8 weeks thereafter. • Injection: 200 mg/20 mL (10 mg/mL) solution in a single-dose vial. Psoriatic Arthritis • 100 mg administered by subcutaneous injection at Week 0, Week 4, **DOSAGE** and every 8 weeks thereafter. TREMFYA can be used alone or in combination with a conventional DMARD (e.g., methotrexate). \_\_\_\_\_ weeks or x 1 year **Ulcerative Colitis** • Induction: 200 mg administered by intravenous infusion over at PRE-MEDICATION least one hour at Week 0, Week 4, and Week 8. • Maintenance: 100 mg administered by subcutaneous injection at ☐ Tylenol PO 650mg ☐1000 MG ☐other \_\_\_\_\_ Week 16, and every 8 weeks thereafter, or 200 mg administered by □ other \_\_\_\_ □ Solumedrol 125mg IV subcutaneous injection at Week 12, and every 4 weeks thereafter. Use the lowest effective recommended dosage to maintain therapeutic □ Benadryl □25mg □50mg □other \_\_\_\_ □IV □PO response. ☐ Medication \_\_\_\_\_ Dose \_\_\_ Route **CONTRAINDICATIONS:** TREMFYA is contraindicated in patients with a history of serious (other) (other) hypersensitivity reaction to guselkumab or to any of the excipients **REQUIRED DOCUMENTATION CHECKLIST:** ICD-10\*: \_\_\_\_\_ Dx Code: \_\_\_\_\_ Patient Demographics Insurance Card/Information Recent labs to include QuantiFERON, and if have CBC, CMP and Hep B surface antigen please send or any other recent labs Current Medication List Other

\_\_\_\_\_ Phone \_\_\_\_\_ Fax \_\_\_